An interventional study of Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) in Glioblastoma, High-Grade Gliomas and Grade III Astrocytoma, sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Medical University of Warsaw · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Glioblastoma with a site in Poland — 8 open to participants now, 10 under way, 1 of them phase 3. Glioblastoma · Poland.
Among the 21 studies in Glioblastoma with a site in Poland, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 17th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →8 of the 21 studies in Glioblastoma with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 18+
Medical University of Warsaw · Sites in Poland
Ages 18+
Prof. Franciszek Lukaszczyk Memorial Oncology Center · Sites in Poland
Ages 18+
Copernicus Memorial Hospital · Sites in Poland
Ages 18–70
Medical University of Warsaw · Sites in Poland
Ages 18–80
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is close to the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 96 across the 20 interventional studies, 200 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.
Medical University of Warsaw has 5 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Glioblastoma with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06271421Poznan University of Medical SciencesNanoTherm In Adjuvant Therapy of Glioblastoma Multiforme | 2027-02-01 |
| NCT06975332Medical University of WarsawLocal, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression | 2027-09 |
| NCT07488754Medical University of WarsawLocal, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Glioblastoma with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.
The aim of this study is to assess the efficacy and safety of local targeted therapy with [225Ac]Ac-DOTA-SP in recurrent glioblastoma.
It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with recurrent WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI progression criteria.
Patients will receive a maximum of six cycles of [225Ac]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.
Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.
Treatment with [225Ac]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.
The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.
Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.
Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.
Background: Brain tumors account for 1.35% of all cancer conditions and cause deaths in 2.2% of cancer patients (Cancer Facts and Figures 2005). The most common type of brain tumors are gliomas. Depending on the age group, they account for 40%-90% of central nervous system tumors. The incidence of malignant gliomas is 0.5-2 per 100,000 people per year. Men are more frequently affected, usually in their 50s and 60s. In the Polish population, approximately 1300 people are diagnosed with gliomas annually, including about 600 cases of malignant gliomas. The standard treatment approach includes surgical treatment, radiotherapy, and chemotherapy. Despite the currently accepted treatment regimen, survival times-depending on the tumor type-range from 1 to 3 years.
In a typical course, regardless of the therapy used, the extent of surgery, and other prognostic factors, the progression of the growth process occurs after some time. The use of chemotherapy extends survival time-depending on the tumor type-by several to several dozen weeks. This data indicates the need to seek other forms of treatment. Since brain gliomas are infiltrative in nature, it seems that an effective drug should exhibit the ability to diffuse freely within the tumor and specifically bind to cancer cells. Selected peptides exhibit such properties.
One of the mechanisms regulating cell (including cancer cell) function involves receptor systems located in the cell membrane. These show high specificity of reaction with specific peptides. The expression of some receptor systems significantly increases in cells of specific tumor types. This property underlies the use of radioisotope-labeled peptides in diagnosis and treatment in oncology. Peptides bind to cancer cells, and ionizing radiation emitted by the attached radioisotope leads to regression of pathological changes. This method is developed only in a few centers worldwide and is currently used, among others, in treating certain types of lymphomas (anti-CD-20 antibody labeled with 90Y or 131I) and neuroendocrine tumors (somatostatin analogs labeled with 90Y, 177Lu).
The benefit of this method is the ability to treat tumors that exhibit resistance to conventional chemotherapy and radiotherapy. Based on own experiences and literature data, it is known that gliomas show increased expression of selected receptor systems. In grade II-IV gliomas, a significant increase in expression for neurokinin-1 (NK-1) receptors, for which substance P is the ligand, has been noted. When administered directly to the tumor, substance P undergoes rapid diffusion and binding to glioma cells.
At the center in Basel (Institute of Nuclear Medicine, University Hospital Basel), a derivative of substance P (1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid) was developed. It was shown that over 95% of gliomas exhibit significantly increased expression of the NK-1 receptor system, and that the proposed peptide has a capacity for specific binding to this type of receptor (out of 34 glioma tissue samples, 32 samples showed significantly increased NK-1 receptor system expression).
Substance P can be labeled with various radioisotopes with differing physical properties, including 90Y and 177Lu-beta radiation emitters. The beta radiation emitted by 90Y has an energy of 2.1 MeV, with a tissue range of about 12 mm. Lutetium emits radiation with an energy of 497 keV, with a range of 1 mm. Limiting factors for the use of beta radiation include its range of action. There is a potential risk of damage to functionally critical brain centers if the tumor is located nearby. This was a premise for the use of alpha radiation emitters. One of the studied radioisotopes is 213Bismuth, which has an energy of 5.8 MeV but a range limited to only 81 μm.
To date, within the framework of the project "Use of Radioisotope-Labeled Substance P in Treating Patients with Brain Tumors" (KB/204/A/201), local glioma treatment has been provided using substance P labeled with alpha emitters 213Bi and 225Ac in the case of confirmed disease recurrence.
Initially, local treatment was performed using [213Bi]Bi-DOTA-SP at an activity of up to 11.2 GBq, achieving good treatment tolerance without clinically significant side effects. The progression-free survival (PFS) was 2.7 months, and the median overall survival (OS) after disease recurrence was nearly twice as long as expected in this patient group, amounting to 10.9 months. The median overall survival from diagnosis was 23.6 months. However, after the start of treatment with [213Bi]Bi-DOTA-SP, the median survival was 7.5 months.
Considering the difficulties in labeling and quality control with a short half-life for 213Bi (46 min), the next step involved treatment with the alpha-emitter 225Ac. A study was conducted evaluating the determination of the maximum tolerated dose of [225Ac]Ac-DOTA-SP, administering activities of 10 MBq, 20 MBq, and 30 MBq. The treatment was well tolerated by patients, with predominantly mild and transient adverse effects such as seizures, aphasia, and hemiparesis. Most adverse effects occurred in patients treated with the 30 MBq dose of [225Ac]Ac-DOTA-SP; hence, the maximum tolerated dose was determined to be 20 MBq. Thrombocytopenia of grade 3 was observed in one study participant, and no grade 3 or 4 toxicity related to the treatment with [225Ac]Ac-DOTA-SP was reported in the other participants. The median OS from diagnosis was 35 months, and from recurrence, it was 13.2 months. The PFS from the start of treatment with [225Ac]Ac-DOTA-SP was 2.4 months.
Studies showed that despite different physical properties (213Bi T1/2 = 46 minutes, 225Ac T1/ 2 = 9.9 days, with 225Ac decaying through alpha particles and 213Bi decaying only once), the survival data for patients treated with [225Ac]Ac-DOTA-SP and [213Bi]Bi-DOTA-SP are similar. Theoretically, the significantly longer half-life of 225Ac should allow for better distribution of [225Ac]Ac-DOTA-SP. The diffusion of the administered radiopharmaceutical is a critical factor for effective local therapy and depends on several factors, such as molecular weight, physicochemical properties, varying extracellular space density, and the post-resection cavity. Small vectors, such as modified SP (1800 Da), lead to rapid diffusion within tissues. However, subsequent administrations may increase the density of the extracellular space due to glioma scarring, leading to heterogeneous diffusion in subsequent injections of the radiopharmaceutical. A limiting factor for local treatment is the very slow rate of diffusion into brain tissue. The diffusion rate in the brain for most substances ranges from 0.15 to 0.6 mm/h. One possible cause could be increased tissue pressure within the tumor and surrounding tissues, which reduces the pressure gradient responsible for the diffusion process. It seems that enhanced diffusion could be achieved by employing forced diffusion via a slow infusion of 0.5 ml/hour of saline into the cavity immediately after administering the radiopharmaceutical. Overall results from both treatment arms exhibit a clear trend for prolonged survival compared to standard therapy.
.
Main Objective: To evaluate the efficacy of local targeted therapy with the alpha-emitter labeled neuropeptide [225Ac]Ac-DOTA-SP (TAT) using a forced diffusion method in cases of recurrence of glioma WHO G3-G4 after first-line treatment.
Secondary Objective: To assess the safety of local targeted therapy with the alpha-emitter labeled neuropeptide [225Ac]Ac-DOTA-SP (TAT).
.
Study Design: Interventional study without a control group. The study is initiated by the investigator, and 225Ac is supplied based on a cooperation agreement between WUM and the Institute for Transuranium Elements (Karlsruhe).
Sponsoring institution: Medical University of Warsaw (WUM). .
Conducting the Study:
Reoperation with Catheter Placement:
PET/CT scan using [68Ga]Ga-PSMA to indicate the site for biopsy and catheter placement.
Resection with biopsy or just the biopsy of the tumor. Cathether placement (for lesions with a diameter >2 cm, up to 3 catheters may be placed). Catheter placement will take place at the Departments of Neurosurgery of either University Clinical Centre (UCK) or National Oncology Institute (NIO). This requires several days of hospitalization.
Local Treatment with [225Ac]Ac-DOTA-SP:
Treatment with [225Ac]Ac-DOTA-SP cannot begin earlier than 2 months after the conclusion of radiotherapy. Chemotherapy may be continued according to the oncologist's recommendations.
Catheter patency controle about one week before planned treatment. Local administration of 5 MBq of 68Ga in a volume of 1-3 ml. Imaging of the brain using PET/CT Siemens Vision 600: 30 minutes after the administration of the tracer. For the first 3 patients, dual-day imaging with 68Ga and [68Ga]Ga-DOTA-SP will be performed to assess biodistribution: 5 MBq of 68Ga in a volume of 1-3 ml; 5 MBq of [68Ga]Ga-DOTA-SP in a volume of 1-3 ml.
Patients will be treated with a maximum of 6 cycles of [225Ac]Ac-DOTA-SP. Preparation of the Radiopharmaceutical: The labeling procedure will be carried out at the Nuclear Medicine Department at WUM. The radioisotope 68Ga is available at the Nuclear Medicine Department; the department has a registered 68Ge/68Ga generator. The team of radiopharmacists at the department possess the necessary qualifications and have been performing radiopharmaceutical labeling using 68Ga for many years. 225Ac will be supplied based on a cooperation agreement between WUM and the Institute for Transuranium Elements (Karlsruhe). After labeling, the prepared product will undergo quality control to verify the labeling efficiency and radiopharmaceutical purity. In any case, if the labeling efficiency is below 90%, the product will not be administered to the patient.
Therapy: Administered activity of [225Ac]Ac-DOTA-SP - 20 MBq in a volume of 10-20% of the resection cavity volume, maximum amount of SP 200 μg (combined for 68Ga and 225Ac).
Radioisotope treatment will be carried out in the UCK hospital, during hospitalization at the Department of Neurosurgery. The length of hospitalization will depend on the patient's condition; from previous experiences, this has typically been 3 days.
Previous experiences have shown good tolerance to treatment with [225Ac]Ac-DOTA-SP. The only noted side effects during therapy were transient facial flushing, and some patients experienced seizures (all patients had seizures noted before therapy as well). For this reason, patients will be hospitalized for 24 hours after therapy in the Department of Neurosurgery (UCK).
However, in the case of poor tolerance to experimental treatment, it will not be continued. Additionally, steroid therapy will be initiated (if it had not been previously). In the event of a seizure, standard anticonvulsant treatment will be applied.
Blood and urine tests will be performed 1, 2, 4, and 24 hours after administering [225Ac]Ac-DOTA-SP.
Assessment of Distribution of [225Ac]Ac-DOTA-SP via SPECT/CT Imaging:
Laboratory tests: Hematology, AST, ALT, Na, K, creatinine, urea, CRP, INR, D-dimers.
Assessment of the Karnofsky Performance Status (KPS). Barthel Index assessment. Assessment of adverse effects. f. Observation: The patient should remain hospitalized at the Department of Neurosurgery (UCK) for 24 hours after treatment with [225Ac]Ac-DOTA-SP.
Physical examination, neurological assessment, adverse events. 24 and 48 hours after the first administration of [225Ac]Ac-DOTA-SP. MRI with contrast will be performed every 2 months to evaluate treatment efficacy and +/- 2 weeks before each administration of [225Ac]Ac-DOTA-SP.
Follow-up visits (including telemedicine options) will be conducted according to Good Clinical Practice and the therapeutic strategy used in the research center, every 2 months during the first 18 months or depending on the clinical status of the patient.
After 18 months, scheduled follow-up visits (including telemedicine options) will take place every 3 months or more frequently if needed.
g. Discontinuation of Therapy: The occurrence of serious adverse events (according to the definition related to TAT).
Coexisting illness preventing further treatment. Progression of the lesion. In the case of the appearance of a new symptomatic solitary lesion in the MRI, treatment may continue at the researcher's discretion, provided that the initially treated lesion or area is stable or regressing.
Withdrawal of the patient from the study. Changes in the patient's condition that, in the investigator's opinion, make further treatment impossible.
The investigator may decide to withdraw the patient from the study for unforeseen reasons, ensuring their safety.
.
Sample Size: The target sample size is 25 patients. Considering the possibility of patient dropouts, the group should include up to 35 patients. Patients will be recruited from those treated at the Departments of Neurosurgery (UCK, NIO).
.
Primary: overall survival (OS) measured from the date of diagnosis.
Secondary: time to progression (progression-free survival, PFS), defined as:
Local progression within \< 4 cm from the border of the primary lesion after resection or, A new lesion on MRI or, Progression of the lesion on MRI by > 25% between two consecutive imaging studies.
In differential diagnostics, radiation necrosis should be included as a treatment-related effect (MRI perfusion and/or biopsy).
Expected Benefits of the Study: The expected outcome of the study is to assess the efficacy and safety of [225Ac]Ac-DOTA-SP with forced diffusion. It is anticipated that the proposed procedure should lead to an extension of survival time and time to disease progression compared to currently used therapeutic methods.
.
Description of Risks and Discomforts for Study Participants: Based on current experiences with the treatment of [225Ac]Ac-DOTA-SP, no clinically significant side effects have been observed. The most frequently reported side effect was seizures (in all patients previously noted before therapy). No clinically significant side effects were identified in laboratory tests. There is no conclusive scientific evidence indicating that the administered local radioactivity poses a risk of developing cancer or hereditary defects. Current data suggest an extension of PFS and OS with the use of local treatment with [225Ac]Ac-DOTA-SP.
.
Study Duration with Justification: The estimated duration of the study is 3 years. Patients who remain alive at the end of the study will be monitored until they report death.
.
Biological Material: During reoperation and catheter placement, material will be collected for histopathological and genetic studies as per standard procedure.
.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with high-grade gliomas (WHO G3-G4) recurrence who are treated with local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT)
Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.
Number of patients experiencing clinical progression (as defined below)
Clinical progression defined by: * reduction in Karnofsky Performance Scale result below 70% OR * new focal neurological deficit or exacerbation of existing deficit OR * necessity to use or increase dexamethasone dose by 50% or more.
Time frame: From enrollment to 18 months
Number of patients experiencing radiological progression (as defined below)
Radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion OR * 25% or more increase in contrast-enhancing lesions despite stable or increasing steroid dose OR * significant increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumour causes.
Time frame: From enrollment to 18 months
Number of patients experiencing local radiological progression (as defined below)
Local radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion within 4 cm from resection cavity OR * 25% or more increase in contrast-enhancing lesions within 4 cm from resection cavity despite stable or increasing steroid dose.
Time frame: From enrollment to 18 months
Plan to share: Yes — Study protocol and anonymised clinical, radiological and molecular data regarding individual patients will be made available as supplementary materials to published articles.
Supporting information: Study protocol
Time frame: from study conclusion in Sep 2027
Access criteria: Data access will be provided to any researchers possessing access to published articles as supplementary materials or via e-mail on reasonable request.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 35 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2027 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →